An increasing number of studies have shown that both ERK and PI3-K/AKT signaling pathways are over-activated in various human cancers including breast cancer, lung cancer, colorectal cancer, pancreatic cancer, malignant melanoma, hepatocellular carcinoma, and cholangiocarcinoma [6-9]. Here, AKT1 is linked to cholangiocarcinoma.